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Abstract
Objectives—To examine the relationship between nonmedical use of prescription opioids and 
heroin initiation from childhood to young adulthood, and to test whether certain ages, racial/
ethnic, and income groups were at higher risk for this transition.
Study design—Among a nationally representative sample of US adolescents assessed in the 
2004-2011 National Surveys on Drug Use and Health cross-sectional surveys (n = 223 534 
respondents aged 12-21 years), discrete-time hazard models were used to estimate the age-specific 
hazards of heroin initiation associated with prior history of nonmedical use of prescription opioids. 
Interactions were estimated between prior history of nonmedical use of prescription opioids and 
age of nonmedical use of prescription opioid initiation, race/ethnicity, and income.
Results—A prior history of nonmedical use of prescription opioids was strongly associated with 
heroin initiation (hazard ratio 13.12, 95% CI 10.73, 16.04). Those initiating nonmedical use of 
prescription opioids at ages 10-12 years had the highest risk of transitioning to heroin use; the 
association did not vary by race/ethnicity or income group.
Conclusions—Prior use of nonmedical use of prescription opioids is a strong predictor of heroin 
use onset in adolescence and young adulthood, regardless of the user's race/ethnicity or income 
group. Primary prevention of nonmedical use of prescription opioids in late childhood may 
prevent the onset of more severe types of drug use such as heroin at later ages. Moreover, because 
the peak period of heroin initiation occurs at ages 17-18 years, secondary efforts to prevent heroin 
use may be most effective if they focus on young adolescents who already initiated nonmedical 
use of prescription opioids.
Adolescence and young adulthood are particularly vulnerable ages for heroin initiation and 
use. In the US, in 2013,18- to 25-year-olds had the highest rates of heroin use.1 Further, the 
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number of adolescents (aged 12-17 years) with past-year heroin dependence increased from 
8000 in 2002-2005 to 13 000 in 2009-2011; among young adults (aged 18-25 years) heroin 
dependence increased from 137 000 to 216 000 in these same periods.2
Such an increase in heroin use and dependence may be partly driven by the transition to 
heroin use among the growing population of youth with a history of nonmedical use of 
prescription opioids.3,4 “Nonmedical prescription opioid use refers to use of prescription 
opioids under physician care at quantities that exceed those prescribed, or use without a 
prescription. Nonmedical use of prescription opioids is the second most frequent type of 
illicit drug use among adolescents and young adults, after marijuana1: youth tend to obtain 
prescription opioids from friends or relatives for free.5,6 Among young adults in 2008-2010, 
frequent users of nonmedical use of prescription opioids experienced a 95% increase in 
heroin use from 2002-2004 to 2008-2010.7 Prescription opioids have a similar chemical 
structure as heroin and, thus, have similar pharmacological effects.8-10 Given the high 
prevalence of nonmedical use of prescription opioids among adolescents and young adults,11 
if there were a strong relationship between nonmedical use of prescription opioids and 
heroin initiation in this age group, a small shift in the prevalence of nonmedical use of 
prescription opioids could have an important population-level impact on heroin use.7
As a first step to informing focused primary prevention efforts, research is needed to identify 
age periods when nonmedical use of prescription opioids initiation may pose a particularly 
high risk for later heroin use and to identify sociodemographic groups that may be at 
considerable risk for experiencing this transition. The link between nonmedical use of 
prescription opioid onset in early adolescence and later development of prescription opioid 
abuse/dependence, as well as evidence suggesting that adolescents have increased biological 
vulnerability to addiction, suggest that early initiation of nonmedical use of prescription 
opioids may also pose a particular risk for future related drug use problems such as heroin 
initiation.12,13 The risk of transition from nonmedical use of prescription opioids to heroin 
use may also be stronger among racial/ethnic minorities and lower-income groups, who, 
once prescription drugs became more expensive and difficult to obtain following the 
introduction of an abuse-deterrent formulation of Oxycontin (Purdue Pharma LP, Stamford, 
Connecticut), may have started to use heroin as a less expensive alternative to prescription 
opioids.4,14,15 To our knowledge, no studies have yet examined heterogeneity in the 
relationship between nonmedical use of prescription opioids and heroin initiation by age or 
social group.
We focus our study on adolescents and young adults, and build on the prior literature by: (1) 
examining whether the risk of heroin initiation in adolescence and young adulthood is 
associated with a prior history of nonmedical use of prescription opioids; and (2) testing 
whether the relationship between nonmedical use of prescription opioids and heroin 
initiation in adolescence and young adulthood varies by age on nonmedical use of 
prescription opioid initiation, race/ethnicity, or family income.
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We used data from the 223 534 adolescents and young adults aged 12-21 years who were 
included in the 2004-2011 National Survey on Drug Use and Health (NSDUH) public use 
files. This study was approved by the Columbia University Mailman School of Public 
Health Institutional Review Board. The NSDUH is the primary source of information on the 
prevalence of drug use in the US population among those aged 12 years and older.2 It is an 
annual cross-sectional survey that collects annual data from residents of households and 
noninstitutional group quarters and from civilians living on military bases.2 As such, the 
NSDUH is representative of the noninstitutionalized, civilian population in the US, and it 
excludes institutionalized individuals including those in residential drug use treatment 
centers. Individuals who do not speak English or Spanish are not interviewed and, therefore, 
not included in the sample.2
The survey uses a multistage area probability sample for each state and the District of 
Columbia and oversamples younger age groups (aged 12-25 years) and Blacks and 
Hispanics. In-person interviews were conducted by a trained interviewer using computer-
assisted personal interviewing. Questions about sensitive behaviors such as drug use were 
administered more privately using audio computer-assisted self-interviewing to increase the 
level of honest reporting of illegal drug use and other sensitive behaviors.16
Respondents were offered a $30 incentive for participation in the survey.
Weighting techniques were used to account for the complex survey design (see Statistical 
Analyses section below). Response rates, in years 2002-2011, varied between 87% and 91% 
and 74% and 77% for household screening and completed interviews, respectively. 
Adolescent and young adult completed interviews weighted response rates varied similarly 
(84% and 90% and 80% and 85%, respectively). Detailed information about the sample 
design and survey methods of NSDUH are found in the NSDUH annual reports from the 
Substance Abuse and Mental Health Services Administration.2
Retrospective reports of nonmedical use of prescription opioids and heroin initiation were 
used to construct a person-time dataset, recording respondents' drug use initiation patterns 
from age 7 years (the earliest age at which respondents reported nonmedical use of 
prescription opioids) until age of censoring (defined as age of heroin initiation or age of 
interview). Initiation of heroin use (n = 7) or nonmedical use of prescription opioids (n = 
656) earlier than age 8 years was not considered because of concerns about validity of 
reports of opioid use in early childhood.
Measures
Our outcome of interest was age of initiation of heroin use among adolescent and young 
adults (ages 12-21 years at date of interview). Individuals were asked: How old were you the 
first time you used heroin?
Our main exposure was prior nonmedical use of prescription opioids history. In NSDUH, 
“nonmedical use” refers to situations in which a subject used a drug that was not prescribed 
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for him/her, or he/she took the drug only for the experience or feeling it caused.2 The 
following information was provided to participants as an attempt to reduce false positive 
responses: “These questions are about prescription pain reliever use. We are not interested in 
your use of over-the-counter pain relievers that can be bought in stores without a doctor's 
prescription.” To improve the identification of pain relievers used in the past, cards with 
pictures of multiple types of prescription opioids were handed to participants (Appendices 1 
and 2; available at www.jpeds.com). Respondents were asked to identify the type used and 
provide the frequency of use. Initiation of drug use was defined based on the response to the 
following question: “How old were you the first time you used any prescription pain reliever 
that was not prescribed for you that or that you took only for the experience or feeling it 
caused?”
For the purpose of our study, we created a time-variant predictor variable that indicated 
whether the previous exposure to nonmedical use of prescription opioids occurred before the 
initiation of heroin use. This variable was coded at each specific period as 0 if a person had 
not used nonmedical use of prescription opioids up to that age and was coded as 1 if the 
person started using nonmedical use of prescription opioids at that age or before.
Categories of age at initiation of nonmedical use of prescription opioid use were also 
generated to account for differences in the risk of heroin use across ages at initiation of 
nonmedical use of prescription opioids (initiation at age 8-9, 10-12, 13-15, 16-18, and 19-21 
years).
Models were adjusted for other types of substance use prior to heroin use. This was defined 
as the initiation of any substance use (ie, cocaine, marijuana, tranquilizers, sedatives, 
stimulant, hallucinogens, methamphetamines, inhalants, crack cocaine, lysergic acid 
diethylamide, and 3,4-methylenedioxy-methamphetamine [ecstasy]), different from 
nonmedical use of prescription opioids, before the initiation of heroin use. We also adjusted 
for prior use of alcohol.
Demographic covariates included the following: (1) age (age round number values from 
7-21 years); (2) sex (male/female); race/ethnicity (Non-Hispanic White, Non-Hispanic 
Black, Hispanic, and Asian/NativeAmerican); (3)past-year family income (<$20 000, $20 
000-$49 999, $50 000-$74 999, and $75 000+); (4) metropolitan statistical area (MSA; MSA 
with more than 1 million persons, MSA with less than1 million persons, or not in a MSA); 
and (5) calendar year of interview (2004-2011). MSA was included to account for potential 
confounding because of the urban-rural differences in both nonmedical use of prescription 
opioid and heroin use.
Statistical Analyses
Exploratory and descriptive analyses using NSDUH weighting were conducted to identify 
proportions of individuals with previous nonmedical use of prescription opioid and heroin 
use and their sociodemographic characteristics. The association between nonmedical use of 
prescription opioid status and the initiation of heroin use was estimated using discrete-time 
hazard models. To select the best-fitting method to model the shape of the baseline hazard 
function, we evaluated the goodness-of-fit of a series of models with different time-ordered 
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sets of polynomials.17 The cubic order polynomial was chosen to model the baseline hazard, 
as it showed lower deviance (indicative of better fit) and also a lower Akaike information 
criterion value, compared with the linear and quadratic models. A lower Akaike information 
criterion represents a smaller distance between the unknown true likelihood function of the 
data and the fitted likelihood function of the model.
We used the following modeling strategy. First, we tested whether prior nonmedical use of 
prescription opioid use was associated with the risk of heroin initiation. To test this, model 1 
included the following covariates: nonmedical use of prescription opioid status, time 
(modeled as a cubic order polynomial), race/ethnicity, previous initiation of any substance 
use (other than nonmedical use of prescription opioid and heroin), previous initiation of 
alcohol use, sex, age, income, MSA, and year of survey. Second, we tested whether the 
association between prior use of nonmedical use of prescription opioid and heroin initiation 
varied by age of nonmedical use of prescription opioid initiation.
Therefore, model 2 also included an interaction term between prior use of nonmedical use of 
prescription opioids and categories of age of initiation of nonmedical use of prescription 
opioids. Third, we tested if the risk of heroin initiation by nonmedical use of prescription 
opioid status differed by race/ethnicity. Model 3 included an interaction term between prior 
use of nonmedical use of prescription opioids and race/ethnicity (eg, Hispanic vs White). 
Fourth, we tested whether the risk of heroin initiation associated with nonmedical use of 
prescription opioid status differed by income. Model 4 thus included an interaction term 
between prior use of nonmedical use of prescription opioids and income category. A Wald 
test of linear hypothesis18 was used to compare model fit between model 1 and models 2-4. 
It tested the null hypothesis that the coefficients of new variables introduced in models 2-4 
were equal to zero (eg, coefficients of the interaction term between prior use of nonmedical 
use of prescription opioids and categories of age of initiation of nonmedical use of 
prescription opioids were equal to zero).
To take into account the complex sampling design, all analyses were based on Taylor series 
approximations using “svy” commands of Stata 13.0 (StataCorp, College Station, Texas).19 
In order to obtain unbiased estimates, analyses were weighted using the provided person-
level analysis weights that account for the selection probability at specific stages or for 
adjustment factors. As multiple NSDUH survey years were used, we divided the person-
level analysis weights by the number of years of NSDUH data used in analyses (8 years).20 
The final weight can be interpreted as the total number of people in the target population 
represented by each record in the sample. Predictive mean neighborhood methods with 
unweighted hot-deck imputation were used to replace missing values with appropriate 
response codes.2
Result
Sociodemographic characteristics of the study population are presented in Table I. The most 
frequently reported initiation age of nonmedical use of prescription opioids was 16-18 years 
of age (45%) followed by 13-15 years (33%). Among the 1385 respondents (0.66% of 
sample; 95% CI 0.62, 0.70) who reported heroin use, 1045 (76%) also reported a history of 
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nonmedical use of prescription opioids (Table I). The incidence of heroin initiation was 67 
per 100 000 person-years.
Figure 1 shows the age-specific fitted probabilities of heroin initiation, as well as the fitted 
probabilities of survival from heroin initiation, given prior history of nonmedical use of 
prescription opioid use. The fitted hazard of heroin initiation increased over time, peaked at 
ages 16-18 years, and decreased thereafter. The hazard of heroin initiation was 13.12 times 
higher among adolescents and young adults with a prior history of nonmedical use of 
prescription opioids than among those with no prior history of nonmedical use of 
prescription opioid use (95% CI 10.73, 16.04) (Table II, model 1). Blacks had a lower 
hazard of heroin initiation than Whites (hazard ratio [HR] 0.16; 95% CI 0.10, 0.25).
The hazard of heroin initiation associated with nonmedical use of prescription opioid use 
varied by age of nonmedical use of prescription opioid initiation. A model that estimated the 
hazard of heroin initiation given prior nonmedical use of prescription opioid separately by 
age category of nonmedical use of prescription opioid initiation provided a better fit to the 
data than a model that estimated the average hazard of heroin initiation given prior 
nonmedical use of prescription opioids across age categories (Table II, model 2: F = 146.81; 
P value < .001). Figure 2 shows the hazard of heroin initiation associated with nonmedical 
use of prescription opioids by age category: the adjusted hazard of heroin initiation 
associated with nonmedical use of prescription opioids was highest when respondents 
started using nonmedical use of prescription opioids at ages 10-12 years (HR 17.77, 95% CI 
13.00, 24.30) followed by ages 13-15 years (HR 15.42, 95% CI 12.44, 19.11), and 8-9 years 
(HR 14.79, 95% CI 6.67, 32.77).
Models 3 and 4 (Table II) evaluated whether the association of nonmedical use of 
prescription opioids with heroin initiation differed by race/ethnicity and income. Specifying 
a separate relationship between nonmedical use of prescription opioids and heroin use by 
racial/ethnic group (model 3) or by income group (model 4), did not improve model fit (F = 
0.83, P = .48 and F = 1.11, P = .35, respectively), indicating that there was no evidence of 
heterogeneity in the effect of nonmedical use of prescription opioids on heroin initiation by 
race/ethnicity or income.
Discussion
We found that prior use of nonmedical use of prescription opioids is a strong predictor of 
heroin use onset among adolescents and young adults. Over the study period, the risk of 
heroin initiation was 13 times higher among respondents who reported prior nonmedical use 
of prescription opioid use than among those who did not previously use nonmedical use of 
prescription opioids. Importantly, the risk of heroin initiation was greatest among 
individuals who were first exposed to nonmedical use of prescription opioids in early 
adolescence (ie, ages 10-12 years). The average risk of heroin initiation was lower among 
Blacks and Hispanics compared with Whites, a finding that is reflective of the changing 
profile of the typical heroin user in the US, from primarily inner-city minorities to suburban 
and rural Whites.21-23 Further, and contrary to our a priori hypothesis, there was no evidence 
of heterogeneity in the effect of nonmedical use of prescription opioids on heroin initiation 
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by race/ethnicity or income, suggesting that the risk of transition from nonmedical use of 
prescription opioids to heroin use may be an important generalizable concern across 
sociodemographic groups.
The fact that those initiating nonmedical use of prescription opioids at ages 10-12 years had 
the highest risk of initiating heroin use by young adulthood has a number of important 
public health implications. First, increased resources for primary nonmedical use of 
prescription opioid prevention efforts focused in late childhood are urgently needed. Such 
programs may have not only the benefit of preventing nonmedical use of prescription 
opioids and related harms, but also a downstream effect of preventing transitions into more 
severe drugs, such as heroin. Second, our results highlight the importance of early 
identification and screening programs to identify adolescents who have initiated nonmedical 
use of prescription opioids. Given that the peak period of heroin initiation was observed to 
be in individuals aged 17-18 years, an important “window of opportunity” exists for 
secondary prevention in early adolescence to prevent transitions to heroin use among 
adolescent nonmedical use of prescription opioid users. Our findings are consistent with 
prior studies, which found that early initiation of nonmedical use of prescription opioids is 
associated with higher risk for later prescription opioid abuse and dependence.5,12
The strong association between nonmedical use of prescription opioid use in early 
adolescence and heroin initiation in young adulthood is a particular concern at the present 
time. Most states have now implemented prescription drug monitoring programs to support 
the appropriate use of prescription drugs, and third-party prescription payment systems run 
by pharmacy benefit managers or health insurers have also been used to detect prescription 
drug abuse.24-26 To the extent that such regulations reduce access and increase the street 
price of prescription opioids, they may have the unintended effect of contributing to drug 
diversion from nonmedical use of prescription opioid to heroin use.14 Hence, concurrent 
investment in substance abuse prevention and treatment programs should be a public health 
priority to prevent such unintended consequences.
This study expands prior research in several ways. First, we examined the relationship 
between nonmedical use of prescription opioid use history and time to heroin initiation 
among adolescents and young adults. This builds on 2 prior studies using NSDUH data, 
which compared the incidence of heroin use by prior nonmedical use of prescription opioid 
status in the 12-year-old and older population.7,23 Second, we tested whether the risk of 
heroin use given a prior history of nonmedical use of prescription opioids was concentrated 
in certain racial/ethnic or income groups. Our study revealed that, at least among adolescents 
and young adults, the risk of transition from nonmedical use of prescription opioid to heroin 
cuts across social groups. Third, we identified an age range, 10-12 years, when initiation of 
nonmedical use of prescription opioid places adolescents at particular risk for later initiation 
of heroin.
Study contributions should be considered in context of the following limitations. First, the 
NSDUH is representative of English and Spanish-speaking adolescents in the US, and not of 
institutionalized individuals, including those in residential drug use treatment centers, who 
may be at particularly high risk for heroin use.27 At the present time, it is unclear whether 
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the magnitude of the association between nonmedical use of prescription opioid and heroin 
use would be different for that population. Second, we may have underestimated the true 
rate of heroin initiation, as some heroin users may not have reported their use in a survey 
interview. Robust and rigorous NSDUH procedures that provide privacy to participants 
(including the use of audio computer-assisted self interview [ACASI]) and protect the 
confidentiality of respondents somewhat allay these concerns. Third, this study is based on 
retrospective reports of age of onset of nonmedical use of prescription opioid and heroin use. 
Respondents may recall their age of onset as later than it actually occurred.28,29 Fourth, the 
NSDUH is a cross-sectional survey; hence, we cannot conclusively establish temporality, 
and our findings should be replicated in a prospective longitudinal study. Fifth, adolescents 
and young adults may not accurately report their family income. This may have limited our 
ability to detect whether family income modified the association between prior nonmedical 
use of prescription opioid and heroin initiation.
In conclusion, prior use of nonmedical use of prescription opioids is a strong predictor of 
heroin use onset among adolescents and young adults, regardless of the user's race/ ethnicity 
or income. Our study shows that 2 windows of opportunity exist for the prevention of heroin 
initiation by investing in the primary prevention of nonmedical use of prescription opioids in 
childhood, before the adolescent years, as well as secondary prevention of heroin use among 
users of nonmedical use of prescription opioids in early adolescence, before the peak of 
heroin use.
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Appendix 1. Prescription opioids included in cards provided to users of 
nonmedical prescription opioid use
1. Darvocet-n®, Darvon®, or Tylenol® with codeine
2. Percocet®, Percodan®, or Tylox®
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13. Phenaphen® with codeine
14. Propoxyphene
15. SK-65®
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Appendix 2. Sample card provided to nonmedical users of prescription 
opioids in the National Survey on Drug Use and Health
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Fitted probability of A, heroin initiation and B, survival by prior nonmedical prescription 
opioid use among adolescents and young adults, NSDUH (2004-2001).
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Fitted HRs of heroin initiation associated with prior nonmedical prescription opioid use, by 
age of nonmedical prescription opioid use initiation (NSDUH, 2004-2011).
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